Goldman Sachs Resumes Gilead Sciences (GILD) at Neutral

Goldman Sachs resumes coverage on Gilead Sciences (NASDAQ: GILD) with a Neutral. PT $81.00.

The firm comments, "GILD's HIV franchise has been eclipsed by hepC in the recent dialogue. While we believe GILD’s single-tablet regimens will allow it to retain share in the HIV market beyond the patent "cliff" and believe ‘7977 for hepC will capture majority share, we see these opportunities as priced into shares."

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $76.23 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
• Keefe, Bruyette & Woods Resumes Canadian Imperial Bank of Commerce (CM:CN) (CM) at Market Perform
• Keefe, Bruyette & Woods Resumes Royal Bank of Canada (RY:CN) (RY) at Market Perform